HMGCR and cancer: Although our reported rate of CAM is higher than the governmentally reported prevalence of cancer in the ≥45 years age group in both countries, our rate is comparable to an American cohort with anti-HMGCR IMNM which reported rates of cancer (6/104, 6%) matching the general population [19].